Keymed Biosciences Co.ltd
Clinical trials sponsored by Keymed Biosciences Co.ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame stubborn hives that antihistamines Can't Results expected Nov 2026 (estimated)
- New injection aims to tame kidney disease Results expected Mar 2027 (estimated)
- First human test of CM583: can this biologic pass the safety check? Results expected Jul 2027 (estimated)
- New hope for Tough-to-Treat multiple myeloma: CM336 enters phase 3 trial Results expected Sep 2027 (estimated)
-
Can a new biologic tame severe eczema Long-Term?
Disease control CompletedThis phase 2 trial is investigating whether CM310, an experimental biologic given by injection, can safely and effectively control moderate-to-severe atopic dermatitis (eczema) over the long term. The study enrolls adults aged 18 to 75 with the condition and will track side effec…
Phase 2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New shot could help teens with severe eczema
Disease control CompletedThis study tested a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The drug is a lab-made antibody that blocks a key protein involved in inflammation. The goal was to see if it improves skin clearing and reduces itch compared to a place…
Phase 3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New eczema drug CM512 enters first human safety trial
Disease control CompletedThis early-stage trial tests a new drug called CM512 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug. 110 participants will receive either CM512 or a placebo, and researchers w…
Phase 1 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New injection shows promise for relieving intense itching
Symptom relief CompletedThis Phase 3 trial tests whether Stapokibart injection can reduce severe itching and skin bumps in adults with prurigo nodularis. About 200 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if itching improves by at least 4 points on a 0…
Phase 3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC